1.1. Jemal A, Bray F, Center M et al. Global cancer statistics. CA: A Cancer J for Clinicians 2011; 61: 69-90.2.2. Mountain C. Revisions in the international system for staging lung cancer. Chest 1997; 111: 1710-7.3.3. Auperin A, Le Pechoux C, Rolland E et al. Meta-analysis of concomitant vs sequential radiochemotherapy in locally advanced non-small cell lung cancer. J Clin Oncol 2010; 28: 2181-90.4.4. Liang H, Zhou H, Li X et al. Chemo-radiotherapy for advanced non-small cell lung cancer: concurrent or sequential? It\'s no longer the question: a systematic review. Int J Cancer 2010; 127 (3): 718-28.5.5. Le Chevalier T, Arriagada R, Quoix E et al. Radiotherapy alone versus combined chemotherapy and radiotherapy in non respectable non-small cell lung cancer: first analysis of a randomized trial in 353 patients. J Natl Cancer Inst 1991; 83: 417−23.6.6. Dillman R, Herndon J, Seagren SL et al. Improved survival in stage III non-small cell lung cancer: seven year follow up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210−5.7.7. Trovo M, Minatel E, Franchin G et al. Radiotherapy vs radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24: 11−5.8.8. Schild S, Stella P, Geyer S et al. Phase III trial comparing chemotherapy plus once daily or twice daily radiotherapy in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 2002; 54: 370−8.9.9. Non Small Cell Lung Cancer Collaborative Group Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909.10.10. Gervais R, Ducolone A, Lechevalier T et al. Conventional radiation (RT) with daily carboplatin (Cb) compared to RT alone after induction chemotherapy (ICT) vinorelbine (Vr)-cisplatine (P): final results of a randomized phase III trial in stage III unrespectable non-small cell lung (NSCLC) cancer: study CRG/BMS/NPC/96 of the French Lung Cancer Study Group NCLCC and IFCT. J Clin Oncol 2005; 23. Abstr. 7016.11.11. Zatloukal P, Petruzelka L, Zemanova M et al. Concurrent vs sequential chemoradiotherapy with cisplatin and vinorelbine in locally advanced non-small cell lung cancer: a randomized study. Lung Cancer 2004; 46: 87-98.12.12. Huber R, Flentje M, Schmidt M et al. Simultaneous chemoradiotherapy compared with radiotherapy alone after induction chemotherapy in inoperable stage IIIA or IIIB non-small cell lung cancer: study CTRT99/97 by the Bronchial Carcinoma Therapy Group. J Clin Oncol 2006; 24: 4397-404.13.13. Fournel P, Robinet G, Thomas P et al. Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small cell lung cancer. Groupe Lyon Saint Etienne d'Oncologie Thoracique Groupe Francais de Pneumo-Cancerologie NPC 95/01 Study. J Clin Oncol 2005; 23: 5910-7.14.14. Furuse K, Fukuoka M, Kawahara M et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with mitomycin, vindesine, and cisplatin in unrespectable stage III non-small cell lung cancer. J Clin Oncol 1999; 17: 2692-9.15.15. Curran W, Scott C, Langer C et al. Long-term benefits is observed in a phase III comparison of sequential vs concurrent chemo-radiation for patients with unrespectable stage III NSCLC: RTOG 9410 (Abstr. 2499). Proc Am Soc Clin Oncol 2003; 22: 621.16.16. Belani C, Choy H, Bonomi P et al. Combined chemoradiotherapy regimens of paclitaxel and carboplatin for locally advanced non-small cell lung cancer: a randomized phase II locally advanced multi-modality protocol. J Clin Oncol 2005; 23: 5883-91.17.17. Gandara D, Chansky K, Albain K et al. Consolidation docetaxel after concurrent chemoradiotherapy in stage IIIB non-small cell lung cancer: phase II Southwest Oncology Group Study S9504. J Clin Oncol 2003; 21: 2004-10.18.18. Girard N, Mornex F. Radiotherapy for locally advanced non-small cell lung cancer. Eur J Cancer 2009; 45 (Suppl. 1): 113-25.19.19. De Ruysscher D, Botterweck A, Dirx M et al. Eligibility for concurrent chemotherapy and radiotherapy of locally advanced lung cancer patients: a prospective population-based study. Ann Oncol 2009; 20 (1): 98-102.20.20. Meert A, Paesmans M, Martin B et al. The role of microvessel density on the survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2002; 87: 694-701.21.21. Fontanini G, Lucchi M, Vignati S et al. Angiogenesis as a prognostic indicator of survival in non-small cell carcinoma: a prospective study. J Natl Cancer Inst 1997; 89: 881-6.22.22. Herbst R, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23: 3243-56.23.23. Hicklin D, Ellis L. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23: 1011-27.24.24. Jain R, Duda D, Clark J et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006; 3: 24-40.25.25. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002; 2: 727-39.26.26. Ferrara N, Hillan K, Gerber H et al. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat Rev Drug Discov 2004; 3: 391-400.27.27. Sandler A, Gray R, Perry M et al. Paclitaxel/carboplatin alone or with bevacizumab for non-small cell lung cancer. N Engl J Med 2006; 355: 2542-50.28.28. Manegold C, von Pawel J, Zatloukal P. BO17704 Study Group et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy naı¨ve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. J Clin Oncol 2007; 25 (Suppl.): LBA7514.29.29. Barbender J, Danenberg K, Metzger R et al. Epidermal growth factor receptor and HER2-neu mRNA expression in non-small cell lung cancer is correlated with survival. Clin Cancer Res 2001; 7: 1850-5.30.30. Mendelsohn J. The epidermal growth factor as a target for cancer therapy. Endoc Relat Cancer 2001; 8: 3-9.31.31. Salomon D, Brandt R, Ciardiello F et al. Epidermal growth factor related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 1995; 19: 183-232.32.32. Ritter C, Arteaga C. The epidermal growth factor receptor-tyrosine kinase: a promising therapeutic target in solid tumors. Semin Oncol 2003; 30 (Suppl. 1): 3-11.33.33. Giaccone G. Epidermal growth factor receptor inhibitors in the treatment of non-small cell lung cancer. J Clin Oncol 2005; 23: 3235-42.34.34. Sequist L, Lynch T. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Ann Rev Med 2008; 59: 429-42.35.35. Shepherd FA, Pereira J, Ciuleanu TE et al. Erlotinib in previously treated non-small cell lung cancer. N Engl J Med 2005; 353: 123-32.36.36. Bezjak A, Tu D, Seymour L et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR.21. J Clin Oncol 2006; 24: 3831-7.37.37. Clark G, Zborowski D, Santabarbara P et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006; 7: 389-94.38.38. Chang A, Parikh P, Thongprasert S et al. Gefitinib (IRESSA) in patients of Asian origin with refractory advanced non-small cell lung cancer: subset analysis from the ISEL study. J Thorac Oncol 2006; 1 (8): 847-55.39.39. Kim E, Hirsh V, Mok T et al. Gefitinib versus docetaxel in previously treated non-small cell lung cancer INTEREST: a randomised phase III trial. Lancet 2008; 22; 372 (9652): 1809-18.40.40. Coate L, Shepherd F. Maintenance therapy in advanced non-small cell lung cancer: evolution, tolerability and outcomes. Ther Adv Med Oncol 2011; 3 (3): 139-57.41.41. Paz-Ares L, Marinis F, Dediu M et al. PARAMOUNT: Phase III study of maintenance pemetrexed (pem) plus best supportive care (BSC) vs placebo plus BSC immediately following induction treatment with pem plus cisplatin for advanced non-squamous non-small cell lung cancer NSCLC. J Clin Oncol 2011; 29 (Suppl.). Abstr. CRA7510.42.42. Cappuzzo F, Coudert B, Wierzbicki R et al. Overall survival analyses from the SATURN phase III placebo-controlled study of erlotinib as first-line maintenance therapy in advanced non-small cell lung cancer NSCLC. Eur J Cancer 2009; 7 (Suppl. 3): 12. Abstr. 22LBA.43.43. European Medicines Agency. Press Release, 19 March 2010. http://www.ema.europa.eu/pdfs/human/press/pr/10757010en.pdf44.44. FDA approves tarceva as a maintenance therapy for advanced non-small cell lung cancer. http://www.gene.com/gene/news/press-releases/display.do?method=detail&id=1272745.45. Rosell R et al. Screening for epidermal growth factor receptor mutations in lung cancer. N Engl J Med 2009; 361 (10): 958-67.46.46. Mok T, Wu Y, Thongprasert S et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009; 361 (10): 947-57.47.47. Mendelsohn J. Epidermal growth factor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 1997; 3: 2703-7.48.48. Li S, Schmits K, Jeffrey P et al. Structural basis for inhibition of the epidermal growth factor receptor by cetuximab. Cancer Cell 2005; 7: 301-11.49.49. Zhang W, Gordon M, Schultheis AM et al. Two immunoglobulin G fragment C-receptor polymorphisms associated with clinical outcome of EGFR-expressing metastatic colorectal patients treated with single agent cetuximab. J Clin Oncol 2006; 24 (18s). Abstr. 3028.50.50. Pirker R, Pereira J, Szczesna A et al. Cetuximab plus chemotherapy in patients with advanced non-small cell lung cancer FLEX: an open label randomized phase III trial. Lancet 2009; 373: 1525-31.51.51. Baumann M, Krause M, Dikomey E et al. EGFR-targeted anti cancer drugs in radiotherapy: preclinical evaluation of mechanisms. Radiother Oncol 2007; 83 (3): 238-48.52.52. Bentzen S, Atasoy B, Daley F et al. Epidermal growth factor receptor expression in pretreatment biopsies from head and neck squamous cell carcinoma as a predictive factor for a benefit from accelerated radiation therapy in a randomized controlled trial. J Clin Oncol 2005; 23: 5560-7.53.53. Dent P, Yacoub A, Contessa J et al. Stress and radiation-induced activation of multiple intracellular signaling pathways. Radiat Res 2003; 159: 283-300.54.54. Liang K, Ang K, Milas L et al. The epidermal growth factor receptor mediates radioresistance. Int J Radiat Oncol Biol Phys 2003; 57: 246-54.55.55. Schmidt-Ullrich R, Valerie K, Fogleman P, Walters J. Radiation-induced autophosphory lation of epidermal growth factor receptor in human malignant mammary and squamous epithelial cells. Radiat Res 1996; 145: 81-5.56.56. Schmidt-Ullrich R, Contessa J, Lammering G et al. ERBB-receptor tyrosine kinases and cellular radiation responses. Oncogene 2003; 22 (37): 5855-65.57.57. Bonner J, Harari P, Giralt J et al. Radiotherapy plus cetuximab for squamous cell carcinoma of the head and neck. N Engl J Med 2006; 354: 567-78.58.58. Blumenschein G, Moughan J, Curran W et al. A phase II study of cetuximab (C-225) in combination with chemoradiation (CRT) in patients (pts) with stage III A/B non-small cell lung cancer (NSCLC). An interim report of the RTOG0324 trial. J Clin Oncol (2007 ASCO Ann Meeting Proceedings Part I) 2007; 25 (Suppl. 18): 7531.59.59. Hughes S, Liong J, Miah A et al. A brief report on the safety study of induction chemotherapy followed by synchronous radiotherapy and cetuximab in stage III non-small cell lung cancer NSCLC: SCRATCH Study. J Thorac Oncol 2008; 3: 648-51.60.60. Govidan R, Bogart X, Wang L et al. Phase II study of pemetrexed, carboplatin, and thoracic radiation with or without cetuximab in patients with locally advanced unrespectable non-small cell lung cancer CALGB 30407. J Clin Oncol 2009; 27 (Suppl. 15). Abstr. 7505.61.61. Dingemans A, Bootsma G, Van Baardwijk A. Determination of standard dose Cetuximab together with concurrent individualized isotoxic accelerated radiotherapy and Cisplatin/Vinorelbine for patients with stage III non-small cell lung cancer NSCLC: a phase I study (NCT 00522886) J Thor Oncol 2011; 6: s489-90.62.62. Ball D, Burmeister B, Mitchell P et al. Phase I trial of gefitinib in combination with concurrent carboplatin, paclitaxel and radiation therapy in patients with stage III non-small cell lung cancer CRITICAL. J Thor Oncol 2007; 2 (8): s633-4.63.63. Ready N, Janne P, Herndon J et al. Chemoradiotherapy and Gefitinib in stage III non-small cell lung cancer NSCLC: a CALGB stratified phase II trial. J Clin Oncol 2006; 24 (18s): 7046.64.64. Ohe Y, Nishiwaki Y et al. Safety and efficacy trial of cisplatin with vinorelbine followed by gefitinib and concurrent thoracic radiotherapy for unrectable locally advanced non-small cell lung cancer. Japan Clin Oncol Group (JCOG) 0402. J Clin Oncol 2010; 28: 15s. Abstr. 7084.65.65. Sacco P, Maione P, Rossi A et al. Combination of radiotherapy and targeted therapies in the treatment of locally advanced non-small cell lung cancer. Target Oncol 2011; 6 (3): 171-80.66.66. Martinez E, Martinez M, Vinolas N et al. Feasibility and tolerability of the addition of erlotinib to 3D thoracic radiotherapy (RT) in patients with unresectable NSCLC: a prospective randomized phase II study. J Clin Oncol 2008; 26 (Suppl. 20). Abstr. 7563.67.67. Choong N, Mauer A, Haraf D et al. Phase I trial of erlotinib-based multimodality therapy for inoperable stage III non-small cell lung cancer. J Thorac Oncol 2008; 3: 1003-11.68.68. Ramella S, Trodella L, Alberti A. Multimodality treatment with radio chemotherapy and erlotinib in advanced NSCLC (MARTE TRIAL). J Thor Oncol 2011; 6 (Suppl. 2): s491-2.69.69. Siva Raja S, Pennell N, Mason D. Induction chemoradiation therapy with EGFR-receptor inhibitor (Erlotinib) for stage IIIA/B non-small cell lung cancer is well tolerated and does not complicate subsequent resection. J Thor Oncol 2011; 6 (Suppl. 2): s1563.70.70. Gorski D, Beckett M, Jaskowiak N et al. Blockage of the vascular endothelial growth factor stress response increases the antitumor effects of ionizing radiation. Cancer Res 1999; 59: 3374-8.71.71. Hartford A, Gohongi T, Fukumura D et al. Irradiation of a primary tumor, unlike surgical removal, enhances angiogenesis suppression at a distal site: potential role of host-tumor interaction. Cancer Res 2000; 60: 2128-31.72.72. Sonveaux P, Brouet A, Havaux X et al. Irradiation-induced angiogenesis through the up-regulation of the nitric oxide pathway: implications for tumor radiotherapy. Cancer Res 2003; 63: 1012-9.73.73. Teicher B, Depuis N, Kusumoto T et al. Antiangiogenic agents can increase tumor oxygenation and response to radiation therapy. Radiat Oncol Inves 1995; 2: 269-76.74.74. Socinski M, Stinchcombe T, Halle J et al. Incorporation of bevacizumab and erlotinib with induction and concurrent carboplatin/paclitaxel and 74 Gy of thoracic radiotherapy in stage III non-small cell lung cancer NSCLC. J Clin Oncol 2009; 27 (Suppl. 15). Abstr. 7528.75.75. Socinski M, Stinchcombe T, Moore D. Phase I-II trial of Bevacizumab (B) end Erlotinib (E) with induction (IND) and concurrent (CON) Carboplatin (CB)/Paclitaxel (P) and 74 Gy of thoracic conformal radiotherapy (TCRT) in stage III non-small cell lung cancer NSCLC. J Thor Oncol 2011; 6 (Suppl. 2): s489.76.76. Center B, Petty W, Ayala D et al. A phase I study of gefitinib with concurrent dose-escalated weekly docetaxel and conformal three-dimensional thoracic radiation followed by consolidative docetaxel and maintenance gefitinib for patients with stage III non-small cell lung cancer. J Thorac Oncol 2010; 5: 69-74.